Mucinex Childrens

Description

Mucinex® children's Cough and Chest Congestion is formulated to provide relief from cough and chest congestion in pediatric patients aged 4 years and older. Each packet contains 5 mg of Dextromethorphan HBr, a cough suppressant, and 100 mg of Guaifenesin, an expectorant. The product is presented in a convenient dosage form of granule packets, with a total of 12 packets per package. The formulation is flavored with Orange Crème to enhance palatability.

Uses and Indications

This drug is indicated for the relief of cough associated with the common cold. It helps to loosen phlegm (mucus) and thin bronchial secretions, facilitating the clearance of mucus from the bronchial passageways. By doing so, it enhances the productivity of coughs, making them more effective in expelling bothersome mucus.

Limitations of Use: This medication is intended for temporary relief of cough and is not a cure for underlying respiratory conditions.

Dosage and Administration

The entire contents of the packet should be emptied onto the tongue and swallowed without chewing the granules to ensure optimal taste.

The recommended dosing is as follows, or as directed by a healthcare professional:

• Adults and children 12 years of age and over: 2 to 4 packets every 4 hours.

• Children 6 years to under 12 years of age: 1 to 2 packets every 4 hours.

• Children 4 years to under 6 years of age: 1 packet every 4 hours.

• Children under 4 years of age: Use is not recommended.

It is important to not exceed 6 doses in any 24-hour period.

Contraindications

Use of this product is contraindicated in patients currently taking a prescription monoamine oxidase inhibitor (MAOI), which includes certain medications for depression, psychiatric or emotional conditions, or Parkinson's disease. Additionally, use is contraindicated for a period of 2 weeks following the discontinuation of an MAOI. Patients should consult a healthcare professional if they are uncertain whether their prescription medication contains an MAOI.

Furthermore, exceeding the recommended dosage is contraindicated while using this product.

Warnings and Precautions

The use of this product is contraindicated in individuals currently taking a prescription monoamine oxidase inhibitor (MAOI), which includes certain medications prescribed for depression, psychiatric or emotional conditions, or Parkinson's disease. Additionally, it should not be used for a period of two weeks following the discontinuation of an MAOI. Healthcare professionals should advise patients to consult with a doctor or pharmacist if they are uncertain whether their prescription medication contains an MAOI.

Prior to using this product, patients should seek medical advice if they have a persistent or chronic cough, particularly if it is associated with smoking, asthma, chronic bronchitis, or emphysema. Furthermore, individuals should consult a healthcare provider if their cough is accompanied by excessive phlegm (mucus).

It is imperative that patients adhere strictly to the recommended dosage and not exceed the directed amount while using this product.

Patients should discontinue use and consult a healthcare professional if their cough persists for more than seven days, recurs, or is accompanied by fever, rash, or a persistent headache, as these symptoms may indicate a serious underlying condition.

For pregnant or breastfeeding individuals, it is essential to seek guidance from a healthcare professional before using this product.

This product should be kept out of reach of children. In the event of an overdose, immediate medical assistance should be sought, or contact with a Poison Control Center should be made without delay.

Side Effects

Patients should be aware of the potential adverse reactions associated with the use of this medication. Serious adverse reactions may occur, particularly in patients who are currently taking or have recently discontinued a prescription monoamine oxidase inhibitor (MAOI). The use of this medication is contraindicated in such cases, and patients should refrain from using it for at least two weeks after stopping an MAOI.

Common adverse reactions may include a persistent or chronic cough, especially in individuals with underlying conditions such as smoking, asthma, chronic bronchitis, or emphysema. Patients experiencing a cough that lasts more than seven days, recurs, or is accompanied by fever, rash, or a persistent headache should stop using the medication and consult a healthcare professional, as these symptoms may indicate a serious condition.

Additionally, patients should seek medical advice before using this medication if they have a cough accompanied by excessive phlegm (mucus). In the event of an overdose, it is crucial to obtain medical assistance immediately or contact a Poison Control Center for guidance.

Drug Interactions

The concomitant use of this product with prescription monoamine oxidase inhibitors (MAOIs) is contraindicated. MAOIs are typically prescribed for the treatment of depression, certain psychiatric conditions, or Parkinson's disease. Patients should not take this product while on MAOIs or for a minimum of two weeks following the discontinuation of an MAOI.

It is essential for patients to consult with a healthcare professional, such as a doctor or pharmacist, to verify whether their current prescription includes an MAOI before initiating treatment with this product.

Packaging & NDC

Below are the non-prescription pack sizes of Mucinex Childrens (dextromethorphan hydrobromide and guaifenesin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 6 years to under 12 years may be administered 1 to 2 packets every 4 hours. For children aged 4 years to under 6 years, the recommended dosage is 1 packet every 4 hours. Use is not recommended for children under 4 years of age.

Geriatric Use

There is no specific information regarding the use of Mucinex Children's Cough and Chest Congestion Mini-Melts Orange Crème in geriatric patients. Therefore, healthcare providers should exercise caution when considering this medication for elderly patients.

Due to the lack of clinical data in this population, it is advisable to monitor geriatric patients closely for any adverse effects or unusual responses to the medication. Additionally, healthcare providers may need to consider individual patient factors, such as comorbidities and concurrent medications, when prescribing this product to elderly patients.

As always, clinical judgment should guide the decision-making process in the treatment of geriatric patients.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure safe use during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the event of an overdose, it is imperative to seek immediate medical assistance or contact a Poison Control Center without delay. Prompt intervention is crucial to mitigate potential adverse effects associated with the overdose.

Healthcare professionals should be vigilant in monitoring for symptoms that may arise from an overdose. While specific symptoms are not detailed in the provided information, it is essential to be aware that they can vary based on the substance involved and the individual’s health status.

Management of an overdose typically involves supportive care and symptomatic treatment. Healthcare providers should assess the patient's condition and implement appropriate measures based on clinical judgment and established protocols. Continuous monitoring and evaluation are recommended to ensure patient safety and effective management of any complications that may arise.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

Reports of side effects have been received through voluntary submissions and surveillance programs. Healthcare professionals and patients are encouraged to report any adverse events to the designated contact number provided for this purpose.

Patient Counseling

Patients should be advised to keep this medication out of reach of children to prevent accidental ingestion. In the event of an overdose, it is crucial to seek medical assistance or contact a Poison Control Center immediately.

Healthcare providers should inform patients that this product should not be used concurrently with prescription monoamine oxidase inhibitors (MAOIs), which are medications prescribed for depression, psychiatric or emotional conditions, or Parkinson's disease. Additionally, patients should be cautioned against using this product for at least two weeks after discontinuing an MAOI. If patients are uncertain whether their prescription medication contains an MAOI, they should be encouraged to consult their doctor or pharmacist.

Patients must be instructed to discontinue use and consult a healthcare professional if their cough persists for more than seven days, returns, or is accompanied by fever, rash, or a persistent headache, as these symptoms may indicate a serious condition.

While using this product, patients should be reminded not to exceed the recommended dosage. Furthermore, healthcare providers should advise patients to seek medical advice before using this product if they have a persistent or chronic cough associated with smoking, asthma, chronic bronchitis, or emphysema, or if their cough is accompanied by excessive phlegm (mucus).

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at a controlled temperature range of 20-25°C (68-77°F) to maintain its integrity and efficacy. Proper storage conditions must be adhered to, ensuring that the product is kept within the specified temperature limits to prevent degradation.

Additional Clinical Information

The medication is administered orally. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Mucinex Childrens, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)